Raymond James & Associates’s Praxis Precision Medicines PRAX Stock Holding History

Raymond James & Associates’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,703	Closed	-$93.5K	–	3942
2023 Q1	$93.5K	Hold	7,703	–	–	﹤0.01%	3663
2022 Q4	$275K	Sell	7,703 -133	-2%	-$4.15K	﹤0.01%	3274
2022 Q3	$267K	Hold	7,836	–	–	﹤0.01%	3255
2022 Q2	$288K	Sell	7,836 -53	-0.7%	-$5.66K	﹤0.01%	3261
2022 Q1	$1.21M	Buy	7,889 +3	+0%	+$616	﹤0.01%	2469
2021 Q4	$2.33M	Hold	7,886	–	–	﹤0.01%	2068
2021 Q3	$2.19M	Buy	7,886 +131	+2%	+$35.5K	﹤0.01%	2037
2021 Q2	$2.13M	Buy	+7,755	New	+$2.78M	﹤0.01%	2055

Other funds holding PRAX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Raymond James & Associates's PRAX Position: Q2 2023 in Review

Raymond James & Associates sold out of Praxis Precision Medicines (PRAX) in Q2 2023, closing a stake of 7,703 shares — an estimated $93.5K sold.

Raymond James & Associates first reported a position in PRAX in Q2 2021 and held it in 8 quarters. The position peaked at $2.33M in Q4 2021. 78 funds tracked by Wall St. Rank hold PRAX as of Q2 2023.

Raymond James & Associates reported no remaining Praxis Precision Medicines position as of Q2 2023 after selling out during the quarter.
Raymond James & Associates sold 7,703 Praxis Precision Medicines shares in Q2 2023, an estimated $93.5K.
Raymond James & Associates first reported a position in Praxis Precision Medicines in Q2 2021 and held it in 8 quarters.
Raymond James & Associates's Praxis Precision Medicines position peaked at $2.33M in Q4 2021.
78 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.